BIOMAT Database Logo BIOMAT Database Logo

A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection. 1998

B U Mueller, and R P Nelson, and J Sleasman, and J Zuckerman, and M Heath-Chiozzi, and S M Steinberg, and F M Balis, and P Brouwers, and A Hsu, and R Saulis, and S Sei, and L V Wood, and S Zeichner, and T T Katz, and C Higham, and D Aker, and M Edgerly, and P Jarosinski, and L Serchuck, and S M Whitcup, and D Pizzuti, and P A Pizzo
HIV and AIDS Malignancy Branch, National Cancer Institute, Bethesda, Maryland, USA.

BACKGROUND Ritonavir, a potent antiretroviral protease inhibitor, has been approved for the treatment of adults and children with human immunodeficiency virus (HIV) infection. In a phase I/II study, we assessed the safety, tolerability, and pharmacokinetic profile of the oral solution of ritonavir in HIV-infected children and studied the preliminary antiviral and clinical effects. METHODS HIV-infected children between 6 months and 18 years of age were eligible. Four dose levels of ritonavir oral solution (250, 300, 350, and 400 mg/m given every 12 hours) were evaluated in two age groups (</=2 years, >2 years). Ritonavir was administered alone for the first 12 weeks and then in combination with zidovudine and/or didanosine. Clinical and laboratory parameters were monitored every 2 to 4 weeks. RESULTS A total of 48 children (median age, 7.7 years; range, 0.5 to 14.4 years) were included in this analysis. Dose-related nausea, diarrhea, and abdominal pain were the most common toxicities and resulted in discontinuation of ritonavir in 7 children. Ritonavir was well absorbed at all dose levels, and plasma concentrations reached a peak 2 to 4 hours after a dose. CD4 cells counts increased by a median of 79 cells/mm3 after 4 weeks of monotherapy and were maintained throughout the study. Plasma HIV RNA decreased by 1 to 2 log10 copies/mL within 4 to 8 weeks of ritonavir monotherapy, and this level was sustained in patients enrolled at the highest dose level of 400 mg/m for the 24-week period. CONCLUSIONS The oral solution of ritonavir has potent antiretroviral activity as a single agent and is relatively well tolerated by children when administered alone or in combination with zidovudine or didanosine.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U

Related Publications

B U Mueller, and R P Nelson, and J Sleasman, and J Zuckerman, and M Heath-Chiozzi, and S M Steinberg, and F M Balis, and P Brouwers, and A Hsu, and R Saulis, and S Sei, and L V Wood, and S Zeichner, and T T Katz, and C Higham, and D Aker, and M Edgerly, and P Jarosinski, and L Serchuck, and S M Whitcup, and D Pizzuti, and P A Pizzo
A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection.
August 1995, Pediatrics,
B U Mueller, and R P Nelson, and J Sleasman, and J Zuckerman, and M Heath-Chiozzi, and S M Steinberg, and F M Balis, and P Brouwers, and A Hsu, and R Saulis, and S Sei, and L V Wood, and S Zeichner, and T T Katz, and C Higham, and D Aker, and M Edgerly, and P Jarosinski, and L Serchuck, and S M Whitcup, and D Pizzuti, and P A Pizzo
Simplified human immunodeficiency virus maintenance therapy in virologically suppressed children with Ritonavir-boosted protease inhibitor monotherapy.
October 2011, The Pediatric infectious disease journal,
B U Mueller, and R P Nelson, and J Sleasman, and J Zuckerman, and M Heath-Chiozzi, and S M Steinberg, and F M Balis, and P Brouwers, and A Hsu, and R Saulis, and S Sei, and L V Wood, and S Zeichner, and T T Katz, and C Higham, and D Aker, and M Edgerly, and P Jarosinski, and L Serchuck, and S M Whitcup, and D Pizzuti, and P A Pizzo
Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group.
July 1996, The Journal of infectious diseases,
B U Mueller, and R P Nelson, and J Sleasman, and J Zuckerman, and M Heath-Chiozzi, and S M Steinberg, and F M Balis, and P Brouwers, and A Hsu, and R Saulis, and S Sei, and L V Wood, and S Zeichner, and T T Katz, and C Higham, and D Aker, and M Edgerly, and P Jarosinski, and L Serchuck, and S M Whitcup, and D Pizzuti, and P A Pizzo
Spontaneous bleeding associated with the use of the protease inhibitor ritonavir in a hemophiliac patient with human immunodeficiency virus infection.
October 1998, The Pediatric infectious disease journal,
B U Mueller, and R P Nelson, and J Sleasman, and J Zuckerman, and M Heath-Chiozzi, and S M Steinberg, and F M Balis, and P Brouwers, and A Hsu, and R Saulis, and S Sei, and L V Wood, and S Zeichner, and T T Katz, and C Higham, and D Aker, and M Edgerly, and P Jarosinski, and L Serchuck, and S M Whitcup, and D Pizzuti, and P A Pizzo
Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone in human immunodeficiency virus-infected patients.
December 2001, Antimicrobial agents and chemotherapy,
B U Mueller, and R P Nelson, and J Sleasman, and J Zuckerman, and M Heath-Chiozzi, and S M Steinberg, and F M Balis, and P Brouwers, and A Hsu, and R Saulis, and S Sei, and L V Wood, and S Zeichner, and T T Katz, and C Higham, and D Aker, and M Edgerly, and P Jarosinski, and L Serchuck, and S M Whitcup, and D Pizzuti, and P A Pizzo
Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children.
March 2003, The Pediatric infectious disease journal,
B U Mueller, and R P Nelson, and J Sleasman, and J Zuckerman, and M Heath-Chiozzi, and S M Steinberg, and F M Balis, and P Brouwers, and A Hsu, and R Saulis, and S Sei, and L V Wood, and S Zeichner, and T T Katz, and C Higham, and D Aker, and M Edgerly, and P Jarosinski, and L Serchuck, and S M Whitcup, and D Pizzuti, and P A Pizzo
The human immunodeficiency virus protease inhibitor ritonavir is potentially active against urological malignancies.
January 2015, OncoTargets and therapy,
B U Mueller, and R P Nelson, and J Sleasman, and J Zuckerman, and M Heath-Chiozzi, and S M Steinberg, and F M Balis, and P Brouwers, and A Hsu, and R Saulis, and S Sei, and L V Wood, and S Zeichner, and T T Katz, and C Higham, and D Aker, and M Edgerly, and P Jarosinski, and L Serchuck, and S M Whitcup, and D Pizzuti, and P A Pizzo
Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice.
February 2004, Endocrinology,
B U Mueller, and R P Nelson, and J Sleasman, and J Zuckerman, and M Heath-Chiozzi, and S M Steinberg, and F M Balis, and P Brouwers, and A Hsu, and R Saulis, and S Sei, and L V Wood, and S Zeichner, and T T Katz, and C Higham, and D Aker, and M Edgerly, and P Jarosinski, and L Serchuck, and S M Whitcup, and D Pizzuti, and P A Pizzo
A fusion inhibitor (FP-21399) for the treatment of human immunodeficiency virus infection: a phase I study.
August 2000, The Journal of infectious diseases,
B U Mueller, and R P Nelson, and J Sleasman, and J Zuckerman, and M Heath-Chiozzi, and S M Steinberg, and F M Balis, and P Brouwers, and A Hsu, and R Saulis, and S Sei, and L V Wood, and S Zeichner, and T T Katz, and C Higham, and D Aker, and M Edgerly, and P Jarosinski, and L Serchuck, and S M Whitcup, and D Pizzuti, and P A Pizzo
Effects of the human immunodeficiency virus-protease inhibitor, ritonavir, on basal and catecholamine-stimulated lipolysis.
June 2005, The Journal of clinical endocrinology and metabolism,
Copied contents to your clipboard!